FNCHQ · Finch Therapeutics Group, Inc.
$9.60
+0.00 (+0.00%)
At close · Jul 30
Going-concern doubt
— flagged Aug 13, 2024
Substantial doubt about the company's ability to continue as a going concern.
“the Company has concluded that there is substantial doubt regarding the Company's ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 13, 2024
Market Cap
$15.42M
Shares
1.61M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Joseph Vittiglio | Chief Business and Legal Officer and Corporate Secretary | $1,024,240 |
| Marc Blaustein | COO | $816,544 |
| Mark Smith | CEO | $536,745 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Mark Smith | CEO | $7,647,005 |
| Joseph Vittiglio | Chief Business and Legal Officer and Corporate Secretary | $2,871,224 |
| Marc Blaustein | COO | $1,851,590 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Mark Smith | CEO | $644,520 |